A health worker wearing personal protective equipment pushes a patient on a wheelchair at a Covid-19 health center in New Delhi. (Photographer: Sumit Dayal/Bloomberg)
5 years ago
May 17, 2021
Track the second wave of Covid-19 in India and the containment and immunisation efforts here.
There is a minuscule but definite risk of thromboembolic events after the administration of Covishield vaccine, according to a report submitted by the National AEFI Committee to the Health Ministry.
Adverse events like bleeding and clotting after a shot of the Oxford-AstraZeneca Covid-19 vaccine -- manufactured locally by the Serum Institute of India -- remains minuscule in India, the Health Ministry said in a statement. “The reporting rate of such cases is around .61/million doses in India, lower than then 4 cases/million reported by U.K.’s regulator.”
However, the committee found no potential risk of thromboembolic events from Bhahrat Biotech’s Covaxin.
These are the symptoms to watch out for within 20 days of receiving any Covid-19 vaccine, particularly Covishield:
Breathlessness
Pain in chest, pain in limbs/pain on pressing limbs/swelling in limbs (arm or calf)
Multiple, pinhead size red spots or bruising of skin in an area beyond the injection site
Persistent abdominal pain with or without vomiting
Seizures in the absence of previous history of seizures with or without vomiting
Severe and persistent headache with or without vomiting (in the absence of previous history of migraine or chronic headache)
Weakness/paralysis of limbs or any particular side or part of the body (including face)
Persistent vomiting without any obvious reason
Blurred vision, pain in the eyes or double vision
Change in mental status, confusion or depressed level of consciousness
Any other symptom or health condition which is of concern to the recipient or the family
The government has advised people with suspected thromboembolic symptoms to report to the health facility where the vaccine was administered.
Delhi: Defence Minister Rajnath Singh handed over the Anti-COVID drug 2DG to Union Health Minister Dr Harsh Vardhan (in pic 1). Dr Harsh Vardhan handed over the Anti-COVID drug 2DG to Delhi AIIMS director Dr Randeep Guleria (in pic 2) pic.twitter.com/4Pl6aBxprw
In view of the warning of high intensity cyclone issued by IMD, the vaccination program scheduled on Monday (17th May) stands cancelled at all MCGM & public vaccination centres.
